Knight Emmanuel M, Schiller Daryl S, Fulman Magda K, Rastogi Rupangi
Department of Pharmacy Services, Montefiore Nyack Hospital, Nyack, NY, USA.
J Pharm Pract. 2020 Oct;33(5):633-639. doi: 10.1177/0897190019825994. Epub 2019 Feb 11.
Limited evidence suggests that prophylactic oral vancomycin may be beneficial in preventing infection (CDI) recurrence, but long-term efficacy is unknown.
To evaluate the long-term efficacy of oral vancomycin prophylaxis (OVP) in preventing CDI recurrence in subjects who require subsequent antibiotic exposure.
A retrospective cohort study was conducted at a community hospital. A total of 91 subjects with a history of CDI between January 2013 and December 2015 who had a subsequent hospitalization requiring systemic antibiotics within 12 months were evaluated. Thirty-two subjects who received prophylaxis with oral vancomycin were compared to 59 subjects who did not receive prophylaxis.
CDI recurrence within 12 months was significantly lower in subjects receiving OVP compared to those who did not receive OVP (6.3% vs 28.8%; odds ratio [OR]: 0.16; 95% confidence interval [CI]: 0.04-0.77; .011) including patients whose previous CDI was an initial episode (3.7% [1/27] vs 28.3% [15/53]; OR: 10.3; 95% CI: 1.28-82.6; = .009).
Use of OVP in subjects with a history of CDI up to 12 months prior to subsequent antibiotic exposure appears to reduce the risk of CDI recurrence for up to 12 months.
有限的证据表明,预防性口服万古霉素可能有助于预防艰难梭菌感染(CDI)复发,但长期疗效尚不清楚。
评估口服万古霉素预防(OVP)在预防需要后续抗生素暴露的受试者CDI复发方面的长期疗效。
在一家社区医院进行了一项回顾性队列研究。对2013年1月至2015年12月期间有CDI病史且在12个月内随后因需要全身使用抗生素而住院的91名受试者进行了评估。将32名接受口服万古霉素预防的受试者与59名未接受预防的受试者进行比较。
与未接受OVP的受试者相比,接受OVP的受试者在12个月内的CDI复发率显著更低(6.3%对28.8%;优势比[OR]:0.16;95%置信区间[CI]:0.04 - 0.77;P = 0.011),包括既往CDI为初次发作的患者(3.7%[1/27]对28.3%[15/53];OR:0.103;95%CI:1.28 - 82.6;P = 0.009)。
在后续抗生素暴露前长达12个月有CDI病史的受试者中使用OVP似乎可将CDI复发风险降低长达12个月。